Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - "ELTROMBOPAG OLAMINE TABLETS" APPROVED FOR MARKETING2024.01.17
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2024.01.16
-
VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE III CLINICAL STUDY OF "SEMAGLUTIDE INJECTION"2024.01.16
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2024.01.15
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2024.01.12
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2024.01.05
-
VOLUNTARY ANNOUNCEMENT - "EVEROLIMUS TABLETS" SUCCEEDED IN PATENT CHALLENGE AND BECAME A FIRST-TO-MARKET GENERIC DRUG2024.01.03
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 20232024.01.02